By Professor Elgene Lim

Journal articles

Lim E; He HH; Chi D; Yeung TY; Schnitt S; Liu SX; Garber J; Richardson A; Brown M, 2012, 'Abstract PD01-08: Differences in estrogen receptor signaling in non-malignant primary ER-positive breast epithelial cells and breast cancer.', Cancer Research, 72, http://dx.doi.org/10.1158/0008-5472.sabcs12-pd01-08

Shen RR; Zhou AY; Kim E; Lim E; Habelhah H; Hahn WC, 2012, 'IκB kinase ε phosphorylates TRAF2 to promote mammary epithelial cell transformation', Molecular and Cellular Biology, 32, pp. 4756 - 4768, http://dx.doi.org/10.1128/MCB.00468-12

Lim E; Ni M; Hazra A; Tamimi R; Brown M, 2012, 'Elucidating the role of androgen receptors and breast cancer.', Clinical Investigation, 2, pp. 1003 - 1011

Lim E; Metzger-Filho O; Winer EP, 2012, 'Natural history of hormone receptor positive breast cancer', Oncology (Williston Park), 26, pp. 688 - 694

Lim E; Lin NU, 2012, 'New insights and emerging therapies in breast cancer brain metastases', Oncology (Williston Park), 26, pp. 652 - 659

Lim E; He HH; Chi D; Garber JE; Richardson A; Brown M, 2012, 'Estrogen receptor (ER) signaling in normal, BRCA (B) 1 and B2 mutation associated, and ER-positive breast cancer (BC) mammary cells.', Journal of Clinical Oncology, 30, pp. 576 - 576, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.576

Oakes SR; Vaillant F; Lim E; Lee L; Breslin K; Feleppa F; Deb S; Ritchie ME; Takano E; Ward T; Fox SB; Generali D; Smyth GK; Strasser A; Huang DCS; Visvader JE; Lindeman GJ, 2012, 'Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737', Proceedings of the National Academy of Sciences of the United States of America, 109, pp. 2766 - 2771, http://dx.doi.org/10.1073/pnas.1104778108

Oakes SR; Vaillant F; Lim E; Lee L; Breslin K; Feleppa F; Deb S; Ritchie ME; Takano E; Ward T; Fox SB; Generali D; Smyth GK; Strasser A; Huang DCS; Visvader JE; Lindeman GJ, 2012, 'Targeting BCL-2–expressing basal-like breast cancer with BH3-mimetics', Hereditary cancer in clinical practice, 10, pp. A25 - A25, http://dx.doi.org/10.1186/1897-4287-10-s2-a25

Ni M; Chen Y; Bailey ST; Imai Y; Liu XS; Brown M, 2011, 'Abstract 941: Targeting androgen receptor in estrogen receptor-negative breast cancer', Cancer Research, 71, pp. 941 - 941, http://dx.doi.org/10.1158/1538-7445.am2011-941

Ni M; Chen Y; Lim E; Wimberly H; Bailey ST; Imai Y; Rimm DL; Shirley Liu X; Brown M, 2011, 'Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer', Cancer Cell, 20, pp. 119 - 131, http://dx.doi.org/10.1016/j.ccr.2011.05.026

Lindeman G; Asselin-Labat M-L; Lim E; Vaillant F; Wu D; Pal B; Sheridan J; Martin J; Smyth G; Visvader J, 2011, 'S17 Breast stem and progenitor cells in cancer – Therapeutic implications', The Breast, 20, pp. S6 - S6, http://dx.doi.org/10.1016/s0960-9776(11)70020-0

Lim E; Winer EP, 2011, 'Will preoperative trials change future clinical practice?', Clinical Investigation, 1, pp. 59 - 73, http://dx.doi.org/10.4155/cli.10.3

Wu D; Lim E; Vaillant F; Asselin-Labat ML; Visvader JE; Smyth GK, 2010, 'ROAST: Rotation gene set tests for complex microarray experiments', Bioinformatics, 26, pp. 2176 - 2182, http://dx.doi.org/10.1093/bioinformatics/btq401

Lim E; Wu D; Pal B; Bouras T; Asselin-Labat ML; Vaillant F; Yagita H; Lindeman GJ; Smyth GK; Visvader JE, 2010, 'Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways', Breast Cancer Research, 12, http://dx.doi.org/10.1186/bcr2560

Lim E; Vaillant F; Wu D; Forrest NC; Pal B; Hart AH; Asselin-Labat ML; Gyorki DE; Ward T; Partanen A; Feleppa F; Huschtscha LI; Thorne HJ; Fox SB; Yan M; French JD; Brown MA; Smyth GK; Visvader JE; Lindeman GJ, 2009, 'Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers', Nature Medicine, 15, pp. 907 - 913, http://dx.doi.org/10.1038/nm.2000

Lim E; Vaillant F; Wu D; Forrest N; Pal B; Gyorki D; Smyth GK; Visvader J; Lindeman G, 2009, 'Investigation of human mammary stem and progenitor subpopulations from BRCA1 mutation carriers and noncarriers', Journal of Clinical Oncology, 27, pp. 504 - 504, http://dx.doi.org/10.1200/jco.2009.27.15_suppl.504

Lim E; Thomson BNJ; Heinze S; Chao M; Gunawardana D; Gibbs P, 2007, 'Optimizing the approach to patients with potentially resectable liver metastases from colorectal cancer', ANZ Journal of Surgery, 77, pp. 941 - 947, http://dx.doi.org/10.1111/j.1445-2197.2007.04287.x

Lim E; Rosenthal MA, 2007, 'Diagnosing cancer: changing patterns of care', INTERNAL MEDICINE JOURNAL, 37, pp. 124 - 126, http://dx.doi.org/10.1111/j.1445-5994.2007.01246.x

Lim E; Browning J; MacGregor D; Davis ID; Cebon JS, 2006, 'Antigen expression in desmoplastic melanoma: a comparison of cancer testis antigen with differentiation antigen expression', Melanoma Research: an international journal of rapid communications of basic and clinical research in melanoma, 16, pp. 347 - 355, http://dx.doi.org/10.1097/01.cmr.0000222588.22493.3f

Rodrigues J; Lim E; McLaughlin S; Faragher I; Skinner I; Chao M; Chapman M; Gibbs P, 2006, 'The influence of language spoken on colorectal cancer diagnosis and management [2]', ANZ Journal of Surgery, 76, pp. 671 - 672, http://dx.doi.org/10.1111/j.1445-2197.2006.03799.x

Lim E; Johns J; McLaughlin S; Faragher I; Skinner I; Chao M; Gibbs P, 2005, 'Subsite-Specific Colorectal Cancer in Diabetic and Nondiabetic Patients', Cancer Epidemiology Biomarkers & Prevention, 14, pp. 1579 - 1582, http://dx.doi.org/10.1158/1055-9965.EPI-05-0176

Lim E; Wicks I; Roberts LJ, 2004, 'Intracardiac thrombosis complicating antiphospholipid antibody syndrome.', Intern Med J, 34, pp. 135 - 137, http://dx.doi.org/10.1111/j.1444-0903.2004.00558.x

Conference Papers

Collier A; Mac Gregor MC; Hilz S; Bardia A; Sohn J; Martin M; Lim E; Martinalbo J; Perez-Moreno PD; Moore HM, 2023, 'Exploratory biomarker analysis of acelERA breast cancer (BC): Phase II study of giredestrant vs. physician's choice of endocrine therapy (PCET) for previously treated, estrogen receptor-positive, HER2-negative advanced BC (ER+, HER2-aBC)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023

Jhaveri KL; Jeselsohn R; Lim E; Hamilton EP; Yonemori K; Beck JT; Kaufman PA; Sammons S; Bhave MA; Saura C; Calvo E; Meniawy T; Larson T; Ma CX; Garcia-Corbacho J; Cao S; Estrem ST; Milata JL; Nguyen B; Beeram M, 2022, 'A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER plus ) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022

Lim E; Brufsky A; Rugo HS; Vogel CL; O'Shaughnessy J; Getzenberg RH; Barnette KG; Rodriguez D; Bird G; Steiner MS; Linden HM, 2022, 'Phase 3 ENABLAR-2 study to evaluate enobosarm and abemaciclib combination compared to estrogen-blocking agent for the second-line treatment of AR+, ER+, HER2-metastatic breast cancer in patients who previously received palbociclib and estrogen-blocking agent combination therapy', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022

Wu SZ; Roden D; Eryani GA; Junankar S; Lim E; Thennavan A; Andersson A; Williams S; Gong J; Fropf R; Fuhrman K; Lundeberg J; Perou C; Swarbrick A, 2021, 'Abstract 129: An integrated multi-omic cellular atlas of human breast cancers', in Cancer Research, American Association for Cancer Research (AACR), pp. 129 - 129, http://dx.doi.org/10.1158/1538-7445.am2021-129

Lim E; Beeram M; Prawira A; Patnaik A; Wang XA; Young SRL; Smyth LM; Hamilton EP, 2021, 'Abstract OT-09-03: EMBER: A phase 1a/b trial of LY3484356, a novel, oral selective estrogen-receptor degrader (SERD), in advanced ER+ breast cancer and endometroid endometrial cancer', in Cancer Research, American Association for Cancer Research (AACR), http://dx.doi.org/10.1158/1538-7445.sabcs20-ot-09-03

Lau B; Segara D; Ong A; Bingham J; Kiely B; Carson E-K; Chen J; Mak C; Warrier S; Hui M; Middleton K; Parker A; Mann B; Lindeman G; Tilley W; Lim E, 2021, 'Abstract OT-09-07: Winpro: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer', in Cancer Research, American Association for Cancer Research (AACR), http://dx.doi.org/10.1158/1538-7445.sabcs20-ot-09-07

Palmieri C; Linden H; Birrell S; Lim E; Schwartzberg LS; Rugo HS; Cobb P; Jain K; Vogel C; O’Shaughnessy JA; Getzenberg RH; Steiner MS; Brufsky A; Overmoyer B, 2021, 'Abstract PD8-10: Efficacy and safety of enobosarm, a selective androgen receptor modulator, to target AR in women with advanced ER+/AR+ breast cancer - final results from an international Phase 2 randomized study', in Cancer Research, American Association for Cancer Research (AACR), http://dx.doi.org/10.1158/1538-7445.sabcs20-pd8-10

Portman N; Milioli H; Alexandrou S; Coulson R; Yong A; Fernandez K; Chia K; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley W; Swarbrick A; Caldon L; Lim E, 2021, 'Abstract PS18-17: Mdm2 inhibition synergises with endocrine therapy or cdk4/6 inhibition for the treatment of estrogen receptor-positive breast cancer', in Cancer Research, American Association for Cancer Research (AACR), http://dx.doi.org/10.1158/1538-7445.sabcs20-ps18-17

Lim E; Boyle F; Okera M; Loi S; Goksu SS; van Hal G; Gable JC; Price GL; Hossain A; Gainford M; Ezquerra MB, 2020, 'The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: An open-label, randomized phase 2 study', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 124 - 125, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000790145400152&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lim E; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia K; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon EC; Portman N, 2020, 'MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 110 - 110

Metzger-Filho O; Mandrekar S; Loibl S; Ciruelos E; Gianni L; Lim E; Miller K; Huang C; Koehler M; Francis P; Valagussa P; Goel S; Prat A; Goetz M; Loi S; Krop I; Carey L; Lanzillotti J; Winer E; Tripathy D; DeMichele A, 2018, 'Abstract OT3-05-07: PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2 positive metastatic breast cancer', in Cancer Research, American Association for Cancer Research (AACR), http://dx.doi.org/10.1158/1538-7445.sabcs17-ot3-05-07

Lim E; Portman N; Alexandrou S; Haupt S; Haupt Y; Caldon E, 2018, 'Abstract P4-04-12: Therapeutic targeting of CDK4/6 inhibitor resistant breast cancer', in Cancer Research, American Association for Cancer Research (AACR), http://dx.doi.org/10.1158/1538-7445.sabcs17-p4-04-12

Singhal H; Chi D; Lim E; He H; Vadhi R; Rao PK; Long HW; Richardson AL; Garber J; Brown M, 2017, 'Estrogen signaling in mature luminal and luminal progenitor cells of BRCA2 carriers and non-carriers', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, DC, Washington, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), DC, Washington, 01 April 2017 - 05 April 2017, http://dx.doi.org/10.1158/1538-7445.AM2017-LB-257

Johnson S; Johnson N; Chi D; Primack B; Cruz C; Stover D; Greifenberg AK; Cao S; O'Connor K; Baselga J; Balmana J; Serra V; Geyer M; D'Andrea A; Lim E; Shapiro GI, 2014, 'Reversal of primary and acquired PARP-inhibitor resistance in BRCA-mutated triple-negative breast cancers by inhibition of transcriptional cyclin-dependent kinases (CDKs)', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, SPAIN, European Org Res & Treatment Canc, Barcelona, pp. 80 - 80, presented at 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, SPAIN, European Org Res & Treatment Canc, Barcelona, 18 November 2014 - 21 November 2014, http://dx.doi.org/10.1016/S0959-8049(14)70364-8

Lim E; He HH; Chi D; Garber JE; Richardson A; Brown M, 2012, 'Estrogen receptor (ER) signaling in normal, BRCA (B) 1 and B2 mutation associated, and ER-positive breast cancer (BC) mammary cells.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2012 - 06 June 2012, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318009800130&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lindeman GJ; Oakes SR; Vaillant F; Lim E; Lee L; Breslin K; Feleppa F; Deb S; Ritchie ME; Takano E; Ward T; Fox SB; Generali D; Smyth GK; Strasser A; Huang DCS; Visvader JE, 2011, 'PD08-02: Targeting BCL-2 Expressing Breast Tumors with BH3-Mimetics – A New Class of Drugs in Breast Cancer?', in Cancer Research, American Association for Cancer Research (AACR), http://dx.doi.org/10.1158/0008-5472.sabcs11-pd08-02

Lindeman GJ; Oakes SR; Vaillant F; Lim E; Lee L; Breslin K; Feleppa F; Deb S; Ritchie ME; Takano E; Ward T; Fox SB; Generali D; Smyth GK; Strasser A; Huang DCS; Visvader JE, 2011, 'Targeting BCL-2 Expressing Breast Tumors with BH3-Mimetics - A New Class of Drugs in Breast Cancer?', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/0008-5472.SABCS11-PDOS-02

Visvader JE; Asselin-Labat M-L; Vaillant F; Lim E; Bouras T; Pal B; Wu D; Smyth G; Lindeman G, 2011, 'Getting abreast of the mammary epithelial hierarchy and breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/1538-7445.AM2011-SY12-03

Lim E; Winer EP, 2011, 'Adjuvant chemotherapy in luminal breast cancers', in Breast, pp. S128 - S131, http://dx.doi.org/10.1016/S0960-9776(11)70309-5

Lim E; Wu D; Pal B; Bouras T; Asselin-Labat M-L; Vaillant F; Yagita H; Lindeman GJ; Smyth GK; Visvader JE, 2010, 'Abstract P4-04-03: Transcriptome Analyses of Mouse and Human Mammary Cell Subpopulations Reveals Multiple Conserved Genes and Pathways', in Cancer Research, American Association for Cancer Research (AACR), http://dx.doi.org/10.1158/0008-5472.sabcs10-p4-04-03

Lim E; Vaillant F; Wu D; Forrest N; Pal B; Gyorki D; Smyth GK; Visvader J; Lindeman G, 2009, 'Investigation of human mammary stem and progenitor subpopulations from BRCA1 mutation carriers and noncarriers', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, presented at 45th Annual Meeting of the American-Society-of-Clinical-Oncology, FL, Orlando, 29 May 2009 - 02 June 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000276606601221&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Posters

Turner NC; Loi S; Moore HM; Chang C-W; Eng-Wong J; Bardia A; Boni V; Sohn J; Jhaveri KL; Lim E, 2021, 'Activity and biomarker analyses from a phase Ia/b study of giredestrant (GDC-9545; G) with or without palbociclib (palbo) in patients with estrogen receptor-positive, HER2-negative locally advanced/metastatic breast cancer (ER+/HER2-LA/mBC)', TX, San Antonio, Vol. 82, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 07 December 2021 - 10 December 2021, http://dx.doi.org/10.1158/1538-7445.SABCS21-PD13-07

Conference Abstracts

Kiedik B; Roden D; Harvey K; Al-Eryani G; Wu S; Hui M; O'Toole S; Lim E; Perou C; Swarbrick A, 2024, 'Abstract PO5-01-09: Exploring cellular heterogeneity of localised breast cancers', in Cancer Research, American Association for Cancer Research (AACR), Vol. 84, http://dx.doi.org/10.1158/1538-7445.sabcs23-po5-01-09

Freelander A; Laven-Law G; Eshraghi L; Geetha N; Somerville P; Pickering M; Alexandrou S; Caldon CE; Tilley WD; Hickey TE; Lim E, 2022, 'Selective Androgen Receptor Modulators in combination with CDK4/6 inhibitors demonstrate anti-cancer activity in preclinical treatment resistant ER plus AR plus breast cancer models', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 83, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 06 December 2022 - 10 December 2022, http://dx.doi.org/10.1158/1538-7445.SABCS22-P4-08-16

Wong K; Sheehan-Dare G; Nguyen A; Ho B; Liu V; Lee J; Brown LJ; Dear RF-G; Chan L; Pathmanandavel S; Sharma S; Malaroda A; Smith I; Lim E; Emmett L, 2022, '⁶⁴Cu-SAR-Bombesin PET-CT imaging in the staging of ER+/PR+/HER2-metastatic breast cancer: Safety, dosimetry, and feasibility in a phase I trial.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022

Wong K; Sheehan-Dare G; Nguyen A; Ho B; Liu V; Lee J; Brown LJ; Dear RF-G; Chan L; Pathmanandavel S; Sharma S; Malaroda A; Smith I; Lim E; Emmett L, 2022, '⁶⁴Cu-SAR-Bombesin PET-CT imaging in the staging of ER+/PR+/HER2- metastatic breast cancer: Safety, dosimetry, and feasibility in a phase I trial.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 3092 - 3092, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.3092

Jhaveri KL; Jeselsohn R; Lim E; Hamilton EP; Yonemori K; Beck JT; Kaufman PA; Sammons S; Bhave MA; Saura C; Calvo E; Meniawy T; Larson T; Ma CX; García-Corbacho J; Cao S; Estrem ST; Milata JL; Nguyen B; Beeram M, 2022, 'A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 1021 - 1021, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.1021

Lim E; Brufsky A; Rugo HS; Vogel CL; O'Shaughnessy J; Getzenberg RH; Barnette KG; Rodriguez D; Bird G; Steiner MS; Linden HM, 2022, 'Phase 3 ENABLAR-2 study to evaluate enobosarm and abemaciclib combination compared to estrogen-blocking agent for the second-line treatment of AR+, ER+, HER2- metastatic breast cancer in patients who previously received palbociclib and estrogen-blocking agent combination therapy.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. TPS1121 - TPS1121, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.tps1121

Back to profile page